000256448 001__ 256448
000256448 005__ 20240403131748.0
000256448 0247_ $$2doi$$a10.3390/cells12040569
000256448 0247_ $$2pmid$$apmid:36831238
000256448 0247_ $$2pmc$$apmc:PMC9954582
000256448 0247_ $$2altmetric$$aaltmetric:142978988
000256448 037__ $$aDZNE-2023-00310
000256448 041__ $$aEnglish
000256448 082__ $$a570
000256448 1001_ $$0P:(DE-2719)2810845$$aKlinkenberg, Michael$$b0$$eFirst author
000256448 245__ $$aInterneuronal In Vivo Transfer of Synaptic Proteins.
000256448 260__ $$aBasel$$bMDPI$$c2023
000256448 3367_ $$2DRIVER$$aarticle
000256448 3367_ $$2DataCite$$aOutput Types/Journal article
000256448 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711373188_22709
000256448 3367_ $$2BibTeX$$aARTICLE
000256448 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000256448 3367_ $$00$$2EndNote$$aJournal Article
000256448 500__ $$aCC BY
000256448 520__ $$aNeuron-to-neuron transfer of pathogenic α-synuclein species is a mechanism of likely relevance to Parkinson's disease development. Experimentally, interneuronal α-synuclein spreading from the low brainstem toward higher brain regions can be reproduced by the administration of AAV vectors encoding for α-synuclein into the mouse vagus nerve. The aim of this study was to determine whether α-synuclein's spreading ability is shared by other proteins. Given α-synuclein synaptic localization, experiments involved intravagal injections of AAVs encoding for other synaptic proteins, β-synuclein, VAMP2, or SNAP25. Administration of AAV-VAMP2 or AAV-SNAP25 caused robust transduction of either of the proteins in the dorsal medulla oblongata but was not followed by interneuronal VAMP2 or SNAP25 transfer and caudo-rostral spreading. In contrast, AAV-mediated β-synuclein overexpression triggered its spreading to more frontal brain regions. The aggregate formation was investigated as a potential mechanism involved in protein spreading, and consistent with this hypothesis, results showed that overexpression of β-synuclein, but not VAMP2 or SNAP25, in the dorsal medulla oblongata was associated with pronounced protein aggregation. Data indicate that interneuronal protein transfer is not a mere consequence of increased expression or synaptic localization. It is rather promoted by structural/functional characteristics of synuclein proteins that likely include their tendency to form aggregate species.
000256448 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000256448 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000256448 650_7 $$2Other$$aParkinson’s disease
000256448 650_7 $$2Other$$aParkinson’s disease
000256448 650_7 $$2Other$$aanimal models
000256448 650_7 $$2Other$$aoligomerization
000256448 650_7 $$2Other$$aprotein spreading
000256448 650_7 $$2Other$$avagus nerve
000256448 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000256448 650_7 $$2NLM Chemicals$$abeta-Synuclein
000256448 650_7 $$2NLM Chemicals$$aVesicle-Associated Membrane Protein 2
000256448 650_2 $$2MeSH$$aMice
000256448 650_2 $$2MeSH$$aAnimals
000256448 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000256448 650_2 $$2MeSH$$abeta-Synuclein: metabolism
000256448 650_2 $$2MeSH$$aParkinson Disease: metabolism
000256448 650_2 $$2MeSH$$aBrain: metabolism
000256448 650_2 $$2MeSH$$aBrain Stem: pathology
000256448 650_2 $$2MeSH$$aVesicle-Associated Membrane Protein 2: metabolism
000256448 7001_ $$0P:(DE-2719)2810665$$aHelwig, Michael$$b1$$udzne
000256448 7001_ $$0P:(DE-2719)9001609$$aPinto-Costa, Rita$$b2$$udzne
000256448 7001_ $$0P:(DE-2719)2812656$$aRollar, Angela$$b3$$udzne
000256448 7001_ $$0P:(DE-2719)2810495$$aRusconi, Raffaella$$b4$$udzne
000256448 7001_ $$0P:(DE-2719)2481741$$aDi Monte, Donato A$$b5$$udzne
000256448 7001_ $$0P:(DE-2719)2772760$$aUlusoy, Ayse$$b6$$eLast author$$udzne
000256448 770__ $$aAlpha-Synuclein Pathology in Human Diseases
000256448 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells12040569$$gVol. 12, no. 4, p. 569 -$$n4$$p569$$tCells$$v12$$x2073-4409$$y2023
000256448 8564_ $$uhttps://pub.dzne.de/record/256448/files/DZNE-2023-00310.pdf$$yOpenAccess
000256448 8564_ $$uhttps://pub.dzne.de/record/256448/files/DZNE-2023-00310.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000256448 909CO $$ooai:pub.dzne.de:256448$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810845$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810665$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001609$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812656$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810495$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2481741$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000256448 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2772760$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000256448 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000256448 9141_ $$y2023
000256448 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000256448 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-07T08:42:17Z
000256448 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000256448 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2022$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-08-01T15:15:06Z
000256448 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000256448 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-08-01T15:15:06Z
000256448 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000256448 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000256448 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELLS-BASEL : 2022$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000256448 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000256448 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000256448 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-08-01T15:15:06Z
000256448 9201_ $$0I:(DE-2719)1013008$$kAG Di Monte$$lNeurodegeneration and Neuroprotection in Parkinson´s Disease$$x0
000256448 980__ $$ajournal
000256448 980__ $$aVDB
000256448 980__ $$aUNRESTRICTED
000256448 980__ $$aI:(DE-2719)1013008
000256448 9801_ $$aFullTexts